1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AVROBIO, Inc.
  6. News
  7. Summary
    AVRO   US05455M1009

AVROBIO, INC.

(AVRO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BTIG Downgrades AVROBIO to Neutral From Buy

01/05/2022 | 06:19am EDT


ę MT Newswires 2022
All news about AVROBIO, INC.
05/16AVROBIO to Present at the H.C. Wainwright Global Investment Conference
BU
05/11Barclays Adjusts AVROBIO's Price Target to $4 from $6, Keeps Overweight Rating
MT
05/10AVROBIO, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/10AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
BU
05/10AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/09AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
05/06AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
05/03AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
BU
04/07AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
04/06AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
More news
Analyst Recommendations on AVROBIO, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -108 M - -
Net cash 2022 82,4 M - -
P/E ratio 2022 -0,35x
Yield 2022 -
Capitalization 33,6 M 33,6 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 122
Free-Float 97,4%
Chart AVROBIO, INC.
Duration : Period :
AVROBIO, Inc. Technical Analysis Chart | AVRO | US05455M1009 | MarketScreener
Technical analysis trends AVROBIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 0,78 $
Average target price 4,86 $
Spread / Average Target 519%
EPS Revisions
Managers and Directors
Geoff MacKay President, Chief Executive Officer & Director
Erik John Ostrowski Chief Financial Officer & Treasurer
Bruce Lee Booth Chairman
Christopher Mason Chief Scientific Officer
Kim Raineri Chief Manufacturing & Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
AVROBIO, INC.-79.62%34
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601